Banca Mediolanum Valuation
Is BMED undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BMED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BMED (€11.04) is trading below our estimate of fair value (€11.93)
Significantly Below Fair Value: BMED is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BMED?
Key metric: As BMED is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BMED's PE Ratio? | |
|---|---|
| PE Ratio | 8.8x |
| Earnings | €924.04m |
| Market Cap | €8.16b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | -2.3x |
Price to Earnings Ratio vs Peers
How does BMED's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.3x | ||
VOYA Voya Financial | 12.3x | 15.0% | US$7.9b |
ABCAPITAL Aditya Birla Capital | 13.3x | 13.7% | ₹496.3b |
2885 Yuanta Financial Holding | 14.2x | 8.2% | NT$429.1b |
LTF L&T Finance | 13.5x | 21.0% | ₹348.4b |
BMED Banca Mediolanum | 8.8x | -3.9% | €8.2b |
Price-To-Earnings vs Peers: BMED is good value based on its Price-To-Earnings Ratio (8.8x) compared to the peer average (13.3x).
Price to Earnings Ratio vs Industry
How does BMED's PE Ratio compare vs other companies in the European Diversified Financial Industry?
| 7 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 7 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: BMED is good value based on its Price-To-Earnings Ratio (8.8x) compared to the European Diversified Financial industry average (10.7x).
Price to Earnings Ratio vs Fair Ratio
What is BMED's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 8.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BMED's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €11.04 | €12.85 +16.4% | 3.5% | €13.50 | €12.00 | n/a | 12 |
| Nov ’25 | €11.46 | €12.65 +10.4% | 4.4% | €13.50 | €11.70 | n/a | 12 |
| Oct ’25 | €11.38 | €12.53 +10.1% | 4.1% | €13.50 | €11.70 | n/a | 12 |
| Sep ’25 | €11.05 | €12.53 +13.3% | 4.1% | €13.50 | €11.70 | n/a | 12 |
| Aug ’25 | €10.77 | €12.23 +13.6% | 5.1% | €13.50 | €10.90 | n/a | 12 |
| Jul ’25 | €10.52 | €12.15 +15.5% | 4.6% | €13.00 | €10.90 | n/a | 12 |
| Jun ’25 | €10.46 | €12.12 +15.8% | 4.7% | €13.00 | €10.90 | n/a | 12 |
| May ’25 | €10.18 | €11.55 +13.5% | 5.5% | €12.80 | €10.80 | n/a | 12 |
| Apr ’25 | €10.32 | €11.38 +10.2% | 3.9% | €12.00 | €10.80 | n/a | 12 |
| Mar ’25 | €10.04 | €11.29 +12.5% | 3.6% | €12.00 | €10.80 | n/a | 12 |
| Feb ’25 | €9.45 | €10.88 +15.0% | 5.8% | €11.80 | €9.50 | n/a | 12 |
| Jan ’25 | €8.50 | €10.58 +24.5% | 6.3% | €11.50 | €9.20 | n/a | 12 |
| Dec ’24 | €8.22 | €10.60 +29.0% | 6.0% | €11.50 | €9.20 | n/a | 12 |
| Nov ’24 | €7.75 | €10.60 +36.8% | 6.0% | €11.50 | €9.20 | €11.46 | 12 |
| Oct ’24 | €8.23 | €10.69 +30.0% | 5.4% | €11.50 | €9.70 | €11.38 | 12 |
| Sep ’24 | €8.48 | €10.68 +26.0% | 5.4% | €11.50 | €9.70 | €11.05 | 12 |
| Aug ’24 | €8.86 | €10.71 +20.9% | 5.4% | €11.50 | €9.70 | €10.77 | 12 |
| Jul ’24 | €8.27 | €10.71 +29.5% | 4.4% | €11.40 | €9.80 | €10.52 | 12 |
| Jun ’24 | €7.97 | €10.78 +35.3% | 5.0% | €11.70 | €9.80 | €10.46 | 12 |
| May ’24 | €8.32 | €10.92 +31.2% | 4.3% | €11.70 | €10.00 | €10.18 | 12 |
| Apr ’24 | €8.39 | €10.96 +30.6% | 4.5% | €11.70 | €10.00 | €10.32 | 12 |
| Mar ’24 | €9.18 | €10.96 +19.4% | 4.5% | €11.70 | €10.00 | €10.04 | 12 |
| Feb ’24 | €8.85 | €9.80 +10.8% | 4.7% | €10.60 | €9.10 | €9.45 | 11 |
| Jan ’24 | €7.83 | €9.72 +24.1% | 4.4% | €10.50 | €9.10 | €8.50 | 11 |
| Dec ’23 | €7.87 | €9.58 +21.7% | 6.2% | €10.50 | €8.60 | €8.22 | 11 |
| Nov ’23 | €7.47 | €9.17 +22.8% | 4.2% | €9.70 | €8.60 | €7.75 | 10 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Berkshire Hathaway
US$1.0t
Through its subsidiaries, engages in the insurance, freight rail transportation, and utility businesses worldwide.
BRKB
US$457.50
7D
2.5%
1Y
38.7%
Amundi
€13.0b
Amundi is a publically owned investment manager.
AMUN
€64.30
7D
-4.3%
1Y
16.2%
MLP
€640.5m
Provides financial services to private, corporate, and institutional clients in Germany.
MLP
€5.86
7D
-1.2%
1Y
20.8%